David Hoying

David Hoying

Auto-generated profile, based on publicly available information

David Hoying

Case Western Reserve University School of Medicine, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
DHDavid Hoying
David Hoying
KMKatherine Miller
Katherine Miller
JTJulia Tanzo
Julia Tanzo
JKJaehee Kim
Jaehee Kim
JBJames Bena
James Bena
MCMohamad R. Chaaban
Mohamad R. Chaaban

27 March 2023 in The Laryngoscope
Verified
Journal Article
Closed access
FHFiras Hentati
Firas Hentati
JKJaehee Kim
Jaehee Kim
DHDavid Hoying
David Hoying
BDBrian D'Anza
Brian D'Anza
KRKenneth Rodriguez
Kenneth Rodriguez

5 October 2023 in American Journal of Rhinology & Allergy
Verified
Journal Article
Closed access
FHFiras Hentati
Firas Hentati
JKJaehee Kim
Jaehee Kim
DHDavid Hoying
David Hoying
BDBrian D’ANza
Brian D’ANza
KRKenneth Rodriguez
Kenneth Rodriguez
Objective: The purpose of this study is to characterize the presentation, outcomes, and barriers to care for White and non-White patients undergoing endoscopic sinus surgery (ESS). Background: ESS is often successful in providing long-term relief for patients suffering from chronic rhinosinusitis (CRS). Literature that uses robust measures of socioeconomic status (SES) and barriers to care to assess ESS outcomes is limited. Methods: A retrospective matched cohort study of patients who underwent ESS for CRS between 1/1/2015 and 6/1/2021 at a single tertiary care academic center was conducted. White and non-White patients were matched 1-to-1 by sex and age (± 5 years). SES was evaluated using the area of deprivation index (ADI). Results: Of the 298 patients included in the study, 149 are White and 149 are non-White, 111 (37.2%) have CRS with nasal polyposis (CRSwNP), 141 (47.3%) had allergic rhinitis, 90 (30.2%) had asthma and 22 (7.4%) required revision ESS. Non-White patients were 3.62 times more likely to present with CRSwNP (95% confidence interval [CI] 2.2-5.96) and had 2.87 times increased odds for requiring revision ESS than age and sex-matched White patients (95% CI 1.090-7.545). The median ADI for non-White (6.00) patients was higher than for White patients (3.00) ( P < .001) and 21.5% more non-White patients presented with Medicaid ( P < .001). Conclusion: Non-White patients undergoing ESS for CRS are more likely to present from areas with fewer resources and be underinsured. Using robust measures of SES, such as ADI, may allow for care to be tailored to patients with barriers to care.

7 December 2025 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
DHDavid Hoying
David Hoying
DKDavid C. Kaelber
David C. Kaelber
MCMohamad R. Chaaban
Mohamad R. Chaaban

22 September 2025 in American Journal of Rhinology & Allergy
Verified
Journal Article
Closed access
DHDavid Hoying
David Hoying
MKMatthew J Kabalan
Matthew J Kabalan
DKDavid C Kaelber
David C Kaelber
RSRaj Sindwani
Raj Sindwani
Background: Previous research has reported inconsistent results when evaluating long-term revision rates of patients undergoing balloon sinus dilation (BSD) compared to primary endoscopic sinus surgery (ESS). Objective: We aimed to compare outcomes and long-term rates of revision surgery in patients with chronic rhinosinusitis without nasal polyps (CRSsP) who underwent primary standalone BSD versus primary ESS. We also wanted to better understand the post-procedure utilization of major healthcare resources between these groups. Methods: Retrospective cohort study using the TriNetX platform to identify patients with CRSsP undergoing standalone BSD versus primary ESS. 1:1 propensity score matching was performed to balance age and gender in each cohort. The primary outcome was revision ESS rates at 1 and 10 years. Secondary outcomes were rates of healthcare utilization and complications, including orbital, cerebrospinal fluid (CSF) leak, and epistaxis within 90 days. Results: After matching, each cohort had 2112 patients. At 1 year, the revision ESS rate was 3.5% in the balloon cohort and 3.5% in the ESS cohort (OR = 0.97, 95% CI: 0.70–1.35). Extending follow-up to 10 years, revision rates were also not statistically different: 5.8% in the balloon cohort and 6.3% in the ESS cohort (OR = 0.92, 95% CI: 0.72–1.19). Patients in the balloon cohort had a lower 90-day risk of inpatient encounters (OR = 0.29, 95% CI: 0.23–0.38), CRS-related patient visits (OR = 0.63, 95% CI: 0.55–0.71), diagnostic nasal endoscopies (OR = 0.57, 95% CI: 0.50–0.65), antibiotic prescriptions (OR = 0.53, 95% CI: 0.43–0.66), and corticosteroid prescriptions (OR = 0.62, 95% CI: 0.53–0.71). Conclusion: No significant difference was observed in revision ESS rates in CRSsP patients who underwent primary BSD versus ESS after 10 years in this large database study. Findings suggest that in appropriately selected patients, BSD offers a durable response and a favorable value proposition in the management of patients with CRSsP.

6 February 2024 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
DHDavid Hoying
David Hoying
IDIan Dorney
Ian Dorney
TOTodd Otteson
Todd Otteson
JTJason Thuener
Jason Thuener
DKDavid C. Kaelber
David C. Kaelber
Objective: To determine the odds of head and neck cancer (HNC) in patients with a concurrent or prior diagnosis of granulomatosis with polyangiitis (GPA). Methods and Materials: The TriNetX Analytics Network, a federated research platform that aggregates de-identified electronic health record data of over 130 million patients worldwide, was queried for patients with at least one ICD-10 encounter diagnosis of GPA. Patients within this group with an encounter diagnosis of cancer of the sinonasal, oral cavity, oropharynx, nasopharynx, and larynx concurrent or after the initial encounter diagnosis of GPA were recorded and compared to a standardized control population to determine odds ratios with a 95% confidence interval (CI). Relevant confounding variables, including human papillomavirus, Epstein Barr virus, tobacco, and alcohol exposure, were balanced between cohorts by 1:1 propensity matching. Results: Of the patients in the GPA cohort, 126 (0.48%) had an ICD-10 diagnosis of HNC. When stratifying by head and neck subsites, 20 (0.08%), 18 (0.07%), 23 (0.09%), 70 (0.27%), and 22 (0.084%) GPA patients had an ICD-10 encounter diagnosis of cancer involving the sinonasal, nasopharynx, larynx, oral cavity, and oropharynx. When comparing the experimental GPA group with the standardized control population after matching, patients in the GPA group had 1.3 times (95% CI: 1.03-1.175) greater odds of HNC when including cases diagnosed after or concurrently with the diagnosis of the vasculitis. There was no statistical difference in the odds of cancer at each anatomical subsite between the GPA and control cohort after matching. Conclusion: Our study identifies a statistically significant increase in the odds of HNC encounter diagnoses in patients with GPA.